Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Molecular profiling of BRAF-V600E-mutant metastatic colorectal cancer in the phase 3 BEACON CRC trial.

Nature medicine - 1 Nov 2024

Kopetz Scott, Murphy Danielle A, Pu Jie, Ciardiello Fortunato, Desai Jayesh, Van Cutsem Eric, Wasan Harpreet Singh, Yoshino Takayuki, Saffari Hedieh, Zhang Xiaosong, Hamilton Phineas, Xie Tao, Yaeger Rona, Tabernero Josep

Abstract excerpt

The BEACON CRC study demonstrated that encorafenib (Enco)+cetuximab (Cetux)±binimetinib (Bini) significantly improved overall survival (OS) versus Cetux + chemotherapy in previously treated patients with BRAF-V600E-mutant mCRC, providing the basis for the approval of the Enco+Cetux regimen in the United States and the European Union. A greater understanding of biomarkers predictive of response to Enco+Cetux±Bini...

Topics

Join the communities discussing this publication.

Antineoplastic Combined Chemotherapy Protocols
Azetidines
Benzimidazoles
Carbamates
Cetuximab

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Neoplasm Metastasis

Proto-Oncogene Proteins B-raf

Source

Open in PubMed Open full text

Identifiers

PMID: 39313594
DOI: 10.1038/s41591-024-03235-9
PMCID: PMC11564101

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Molecular profiling of BRAF-V600E-mutant metastatic colorectal cancer in the phase 3 BEACON CRC trial.PMID 39313594Read ↗

Exploratory Analysis of Biomarkers and Treatment Outcomes from the COLUMBUS Study in BRAF V600E/K-Mutant Advanced or Metastatic Melanoma.Semantic proximity Read ↗

Treatment of BRAF-V600E mutant metastatic colorectal cancer: new insights and biomarkers.Semantic proximity Read ↗

Binimetinib, encorafenib and cetuximab (BEACON Trial) combination therapy for patients with BRAF V600E-mutant metastatic colorectal cancer.Semantic proximity Read ↗

ANCHOR CRC: Results From a Single-Arm, Phase II Study of Encorafenib Plus Binimetinib and Cetuximab in Previously Untreated BRAFV600E-Mutant Metastatic Colorectal Cancer.Semantic proximity Read ↗

The Evolving Treatment Landscape in BRAF-V600E-Mutated Metastatic Colorectal Cancer.Semantic proximity Read ↗

Molecular profiling of metastatic colorectal tumors using next-generation sequencing: a single-institution experience.Semantic proximity Read ↗

The Oncology Biomarker Discovery framework reveals cetuximab and bevacizumab response patterns in metastatic colorectal cancerSemantic proximity Read ↗

Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E-Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study.Semantic proximity Read ↗

Management of BRAF-mutant metastatic colorectal cancer: a review of treatment options and evidence-based guidelines.Semantic proximity Read ↗

A phase II study of daily encorafenib in combination with biweekly cetuximab in patients with BRAF V600E mutated metastatic colorectal cancer: the NEW BEACON study.Semantic proximity Read ↗

Phase 1/2 trial of encorafenib, cetuximab, and nivolumab in microsatellite stable BRAFV600E metastatic colorectal cancer.Semantic proximity Read ↗

BRAF-mutated colorectal adenocarcinomas: Pathological heterogeneity and clinical implications.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.